To cite this paper use one of the standards below:
Parkinson’s disease is a neurodegenerative disorder characterized by the accumulation of intracellular inclusions enriched in amyloid fibrils formed by the protein α-synuclein, therefore, the aggregation of α-synuclein into fibrillar species is considered an important target for the development of therapeutic strategies. Previous studies have shown that tetracycline-family antibiotics, particularly doxycycline, can interfere with α-synuclein aggregation and modify the formation of amyloid species, however, the low aqueous solubility and hydrophobic character of some compounds in this class may limit their application and bioavailability. In this context, nanostructured lipid carriers such as cubosomes represent a promising drug delivery system for the encapsulation of hydrophobic molecules. This project aims to investigate whether the encapsulation of demeclocycline, a tetracycline-family compound, in cubosomes can provide a suitable delivery system while preserving its potential anti-amyloid activity against α-synuclein aggregation. Initially, cubosomes will be prepared using a bottom-up method based on phytantriol and Pluronic F127 and subsequently characterized. Demeclocycline will then be incorporated into the lipid nanostructures, and the physicochemical properties and stability of the resulting system will be investigated. The interaction between α-synuclein, demeclocycline and the cubosomes will subsequently be studied in order to evaluate possible changes in the protein aggregation process. Small-angle X-ray scattering (SAXS), fluorescence correlation spectroscopy (FCS) and Dynamic Light Scattering (DLS) will be employed to characterize structural and dynamic changes in the system and to investigate the formation and evolution of aggregated species. Comparisons between free demeclocycline and the encapsulated compound will allow the assessment of whether cubosome-based delivery affects the interaction of the drug with α-synuclein and its ability to interfere with amyloid formation. The study may contribute to a better understanding of the interactions between lipid nanostructures, therapeutic compounds and amyloidogenic proteins, while exploring a potential drug repurposing strategy for compounds of the tetracycline family. More broadly, the proposed approach may contribute to the development of nanostructured delivery systems for hydrophobic compounds with potential applications in neurodegenerative diseases.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper